AIBMR & Ganeden Receive FDA GRAS Status For BC30 Probiotic

With AIBMR at the research helm, Ganeden Biotech receives “No Objection” letter from the FDA; GanedenBC30 is first Bacillus strain to receive GRAS status.

John R. Endres, ND, Chief Scientific Officer, AIBMR Life Sciences, and full member of the Society of Toxicology and lead panel expert for the GanedenBC30 GRAS self determination and FDA notification said, “Through their tremendous commitment to science and safety, Ganeden Biotech is a model for the probiotic and functional foods industries.”